These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 27883322)
1. Molecular Biology and Genetic Mechanisms in the Progression of the Malignant Skin Melanoma. Pejkova S; Dzokic G; Tudzarova-Gjorgova S; Panov S Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2016 Nov; 37(2-3):89-97. PubMed ID: 27883322 [TBL] [Abstract][Full Text] [Related]
2. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation]. Lázár V Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354 [TBL] [Abstract][Full Text] [Related]
3. Roads to melanoma: Key pathways and emerging players in melanoma progression and oncogenic signaling. Paluncic J; Kovacevic Z; Jansson PJ; Kalinowski D; Merlot AM; Huang ML; Lok HC; Sahni S; Lane DJ; Richardson DR Biochim Biophys Acta; 2016 Apr; 1863(4):770-84. PubMed ID: 26844774 [TBL] [Abstract][Full Text] [Related]
4. Molecular pathogenesis of cutaneous melanocytic neoplasms. Ibrahim N; Haluska FG Annu Rev Pathol; 2009; 4():551-79. PubMed ID: 19400696 [TBL] [Abstract][Full Text] [Related]
5. Ras, Raf, and MAP kinase in melanoma. Solus JF; Kraft S Adv Anat Pathol; 2013 Jul; 20(4):217-26. PubMed ID: 23752084 [TBL] [Abstract][Full Text] [Related]
6. Genetic alterations in signaling pathways in melanoma. Haluska FG; Tsao H; Wu H; Haluska FS; Lazar A; Goel V Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2301s-2307s. PubMed ID: 16609049 [TBL] [Abstract][Full Text] [Related]
7. Exploration of genetic alterations in human endometrial cancer and melanoma: distinct tumorigenic pathways that share a frequent abnormal PI3K/AKT cascade. Ogawa K; Sun C; Horii A Oncol Rep; 2005 Dec; 14(6):1481-5. PubMed ID: 16273242 [TBL] [Abstract][Full Text] [Related]
8. Use of human tissue to assess the oncogenic activity of melanoma-associated mutations. Chudnovsky Y; Adams AE; Robbins PB; Lin Q; Khavari PA Nat Genet; 2005 Jul; 37(7):745-9. PubMed ID: 15951821 [TBL] [Abstract][Full Text] [Related]
9. Melanoma: molecular pathogenesis and emerging target therapies (Review). Russo AE; Torrisi E; Bevelacqua Y; Perrotta R; Libra M; McCubrey JA; Spandidos DA; Stivala F; Malaponte G Int J Oncol; 2009 Jun; 34(6):1481-9. PubMed ID: 19424565 [TBL] [Abstract][Full Text] [Related]
10. Melanoma mutagenesis and aberrant cell signaling. Bello DM; Ariyan CE; Carvajal RD Cancer Control; 2013 Oct; 20(4):261-81. PubMed ID: 24077403 [TBL] [Abstract][Full Text] [Related]
11. Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling. Bhatt KV; Spofford LS; Aram G; McMullen M; Pumiglia K; Aplin AE Oncogene; 2005 May; 24(21):3459-71. PubMed ID: 15735667 [TBL] [Abstract][Full Text] [Related]
12. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. Tsao H; Goel V; Wu H; Yang G; Haluska FG J Invest Dermatol; 2004 Feb; 122(2):337-41. PubMed ID: 15009714 [TBL] [Abstract][Full Text] [Related]
13. MicroRNAs in the pathogenesis of malignant melanoma. Glud M; Gniadecki R J Eur Acad Dermatol Venereol; 2013 Feb; 27(2):142-50. PubMed ID: 22621697 [TBL] [Abstract][Full Text] [Related]